CMV Infection of Human Sinusoidal Endothelium Regulates Hepatic T Cell Recruitment and Activation by Bruns, Tony et al.
 
 
CMV Infection of Human Sinusoidal Endothelium
Regulates Hepatic T Cell Recruitment and
Activation
Bruns, Tony; Zimmermann, Henning; Pachnio, Annette; Li, Ka-Kit; Trivedi, Palak; Reynolds,
Gary; Hubscher, Stefan; Stamataki, Zania; Badenhorst, Paul; Weston, Christopher; Moss,
Paul; Adams, David
DOI:
10.1016/j.jhep.2015.02.046
License:
Other (please specify with Rights Statement)
Document Version
Peer reviewed version
Citation for published version (Harvard):
Bruns, T, Zimmermann, HW, Pachnio, A, Li, K-K, Trivedi, PJ, Reynolds, G, Hubscher, S, Stamataki, Z,
Badenhorst, P, Weston, CJ, Moss, PA & Adams, DH 2015, 'CMV Infection of Human Sinusoidal Endothelium
Regulates Hepatic T Cell Recruitment and Activation', Journal of Hepatology.
https://doi.org/10.1016/j.jhep.2015.02.046
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
NOTICE: this is the author’s version of a work that was accepted for publication in Journal of Hepatology. Changes resulting from the
publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be
reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was
subsequently published in Journal of Hepatology, DOI: 10.1016/j.jhep.2015.02.046.
Eligibility for repository checked April 2015
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
Accepted Manuscript
CMV Infection of Human Sinusoidal Endothelium Regulates Hepatic T Cell
Recruitment and Activation
Tony Bruns, Henning W. Zimmermann, Annette Pachnio, Ka-Kit Li, Palak J.
Trivedi, Gary Reynolds, Stefan Hubscher, Zania Stamataki, Paul W. Badenhors,
Christopher J. Weston, Paul A. Moss, David H. Adams
PII: S0168-8278(15)00168-3
DOI: http://dx.doi.org/10.1016/j.jhep.2015.02.046
Reference: JHEPAT 5600
To appear in: Journal of Hepatology
Received Date: 11 December 2014
Revised Date: 16 February 2015
Accepted Date: 18 February 2015
Please cite this article as: Bruns, T., Zimmermann, H.W., Pachnio, A., Li, K-K., Trivedi, P.J., Reynolds, G.,
Hubscher, S., Stamataki, Z., Badenhors, P.W., Weston, C.J., Moss, P.A., Adams, D.H., CMV Infection of Human
Sinusoidal Endothelium Regulates Hepatic T Cell Recruitment and Activation, Journal of Hepatology (2015), doi:
http://dx.doi.org/10.1016/j.jhep.2015.02.046
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting proof before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
  
 1
Resubmission of Manuscript no. JHEPAT-D-14-02440R1 1 
 2 
Title:  3 
CMV Infection of Human Sinusoidal Endothelium Regulates Hepatic T Cell 4 
Recruitment and Activation 5 
 6 
Authors: 7 
1. Tony Bruns (1, 2, 3)   tony.bruns@med.uni-jena.de 8 
2. Henning W. Zimmermann (1, 4) henzimmermann@ukaachen.de  9 
3. Annette Pachnio (5)   a.pachnio@bham.ac.uk  10 
4. Ka-Kit Li (1)    kkl5@doctors.org.uk   11 
5. Palak J. Trivedi (1)   p.j.trivedi@bham.ac.uk  12 
6. Gary Reynolds (1, 6)   g.m.reynolds@bham.ac.uk  13 
7. Stefan Hubscher (1, 6)   s.g.hubscher@bham.ac.uk  14 
8. Zania Stamataki (1)   z.stamataki@bham.ac.uk  15 
9. Paul W. Badenhorst (7)   p.w.badenhorst@bham.ac.uk  16 
10. Christopher J. Weston (1)  c.j.weston@bham.ac.uk  17 
11. Paul A. Moss (5)   p.moss@bham.ac.uk  18 
12. David H. Adams (1)   d.h.adams@bham.ac.uk  19 
 20 
Affiliations: 21 
1. NIHR Biomedical Research Unit and Centre for Liver Research, University of 22 
Birmingham, Birmingham, United Kingdom 23 
2. Department of Internal Medicine IV, Jena University Hospital, Friedrich Schiller 24 
University of Jena, Jena, Germany  25 
  
 2
3. Center for Sepsis Control and Care, Jena University Hospital, Friedrich Schiller 1 
University of Jena, Jena, Germany  2 
4. Department of Medicine III, University Hospital Aachen, RWTH Aachen University, 3 
Aachen, Germany 4 
5. School of Cancer Sciences, University of Birmingham, Birmingham, United 5 
Kingdom 6 
6. Department of Cellular Pathology, Queen Elizabeth Hospital Birmingham, 7 
Birmingham, UK 8 
7. School of Immunity and Infection, University of Birmingham, Birmingham, UK 9 
 10 
Corresponding authors: 11 
1. David H. Adams, MD, FRCP, FMedSci, Centre for Liver Research, 5th Floor IBR, 12 
College of Medical and Dental Sciences, Medical School Building, University of 13 
Birmingham, Edgbaston, Birmingham, B15 2TT, UK. Telephone +44 (0)121 415 14 
8702. Email: d.h.adams@bham.ac.uk  15 
2. Tony Bruns, MD, Department of Internal Medicine IV (Gastroenterology, 16 
Hepatology, Infectious Disease), Jena University Hospital, Erlanger Allee 101, 17 
07740 Jena, Germany. Telephone +49 (0) 3 641 9 322 303. Telefax: +49 (0) 3 641 18 
9 324 222. Email: tony.bruns@med.uni-jena.de  19 
 20 
Electronic word count: 21 
Figures: 7 22 
Tables: 0 23 
Abstract word count: 199/250 24 
Manuscript word count (incl. abstract, figure legends, references):  5990/6000 25 
Supplementary figures: 7  26 
  
 3
Conflict of interest: 1 
The authors have no conflicting financial interests.  2 
 3 
Financial support: 4 
Tony Bruns was supported by the German Research Foundation (DFG BR4182/1-1) 5 
and receives support from the German Federal Ministry of Education and Research 6 
(BMBF, 01 E0 1002).  7 
 8 
Authors’ contributions: 9 
Study concept and design: TB, PAM, DHA 10 
Acquisition of data: TB, HWZ, AP, KKL, GMR, PWB 11 
Analysis and interpretation of data: TB, SGH, PWB, PAM, DHA 12 
Drafting of the manuscript: TB, DHA 13 
Critical revision of the manuscript for important intellectual content: TB, HWZ, AP, 14 
KKL, PJT, GMR, SGH, ZS, PWB, CJW, PAM, DHA 15 
Statistical analysis: TB, PWB 16 
Technical or material support: AP, KKL, PJT, GMR, ZS, PWB, CJW, PAM, DHA 17 
Study supervision: DHA 18 
 19 
Acknowledgements: 20 
We thank the staff at the Liver Transplant Unit, Queen Elizabeth Hospital 21 
Birmingham, UK for their help with sample collection and the patients for donating 22 
blood and tissue. We also thank Gill Muirhead and Janine Youster for their help with 23 
HSEC isolation and culture, Stephen Kissane for performing SAGE analysis, Richard 24 
Stanton for providing recombinant HCMV, and Sukhdeep Galsinh for measuring 25 
type-I interferons.  26 
  
 4
 1 
Key words: 2 
Liver Immunology; Cytomegalovirus; Liver Sinusoidal Endothelial Cells; 3 
Transendothelial Migration   4 
  
 5
Abbreviations used: 1 
BAC bacterial artificial chromosome 2 
CLEVER-1 common lymphatic endothelial and vascular endothelial receptor-1 3 
EC endothelial cells  4 
ECM endothelial cell medium 5 
EPCR endothelial protein C receptor 6 
ETM endothelial transmigration 7 
FI fluorescence intensity 8 
Foxp3 forkhead box P3 9 
HCMV human cytomegalovirus 10 
HFFF2 human fetal foreskin fibroblasts 11 
HSEC hepatic sinusoidal endothelial cells 12 
ICAM-1 intercellular adhesion molecule-1 13 
IMC isotype-matched control 14 
LCL lymphoblastoid cell lines 15 
LFA-3 lymphocyte function-associated antigen 3 16 
MBCD methyl-β-cyclodextrin 17 
MCVM murine cytomegalovirus 18 
MOI multiplicity of infection 19 
p.i. post infection 20 
SAGE serial analysis of gene expression 21 
TEM effector memory T cells 22 
Treg regulatory T cells 23 
VAP-1 vascular adhesion protein-1 24 
VCAM-1 vascular cell adhesion molecule-1  25 
  
 6
BACKGROUND & AIMS: Human cytomegalovirus infection (HCMV) is associated 1 
with an increased morbidity after liver transplantation by facilitating allograft rejection 2 
and accelerating underlying hepatic inflammation. We hypothesized that human 3 
hepatic sinusoidal endothelial cells infected with HCMV possess the capacity to 4 
modulate allogeneic T cell recruitment and activation thereby providing a plausible 5 
mechanism of how HCMV infection is able to enhance hepatic immune activation. 6 
METHODS: Human hepatic sinusoidal endothelial cells were isolated from explanted 7 
livers and infected with recombinant endotheliotropic HCMV. We used static and 8 
flow-based models to quantify adhesion and transendothelial migration of allogeneic 9 
T cell subsets and determine their post-migratory phenotype and function.  10 
RESULTS: HCMV infection of primary human hepatic sinusoidal endothelial cells 11 
facilitated ICAM-1 and CXCL10-dependent CD4 T cell transendothelial migration 12 
under physiological levels of shear stress.  Recruited T cells were primarily non-virus-13 
specific CXCR3hi effector memory T cells, which demonstrated features of LFA3-14 
dependent Th1 activation after migration. In parallel, regulatory T cells were more 15 
strongly recruited via infected hepatic endothelium and retained a suppressive 16 
phenotype following transmigration. 17 
CONCLUSIONS: The ability of infected hepatic endothelium to recruit distinct 18 
functional CD4 T cell subsets shows how HCMV facilitates hepatic inflammation and 19 
immune activation and may simultaneously favor virus persistence. 20 
  21 
  
 7
Introduction 1 
Hepatic sinusoidal endothelial cells (HSEC) differ from endothelial cells (EC) in other 2 
vascular beds. Leukocytes entering the liver through the sinusoids undergo 3 
sequential interactions with HSECs, which are selectin-independent and involve non-4 
classical adhesion molecules[1, 2]. In addition, HSEC are capable of presenting and 5 
cross-presenting exogenous antigen to CD4 and CD8 T cells thereby contributing to 6 
local immune regulation in the liver[3, 4]. As a scavenger cell population, HSEC also 7 
bind and capture circulating hepatotropic viruses to facilitate infection of 8 
hepatocytes[5–7]. Human cytomegalovirus (HCMV) is a ubiquitous herpes virus that 9 
persists for the life of the host after initial infection and infects many cell types 10 
including epithelial, mesenchymal, and EC during acute infection[8].  11 
 12 
The liver represents a major target leading to virus-induced hepatitis and liver cell 13 
damage in immunocompetent and immunocompromised hosts. Hepatocytes are 14 
permissive for cytomegalovirus infection in vivo and in vitro[9], but hepatocyte-15 
derived murine CMV (MCMV) fails to leave the liver but infects adjacent EC[10, 11]. 16 
Although it has long been recognized that EC in many organs are capable of 17 
harboring viral DNA during CMV latency[12], sinusoidal EC have only recently been 18 
identified as the source of MCMV latency and reactivation within the liver[13]. 19 
Consistent with this previous studies report that HCMV infection of HSEC frequently 20 
precedes hepatocyte infection in liver allograft recipients[14]. In the organ transplant 21 
setting HCMV infection of the seronegative recipient is associated with an increased 22 
risk of graft-loss and death after liver transplantation[15] and HCMV infection can 23 
promote hepatic inflammation and facilitate chronic organ rejection[16]. The 24 
molecular basis of this observation is not clear, but MCMV infection of murine HSEC 25 
activates a gene expression pattern associated with increased expression of 26 
  
 8
chemokines and adhesion molecules and the promotion of an immunogenic CD8 T 1 
cell response[17].  2 
 3 
We hypothesized that HCMV infection will modulate the ability of human HSEC to 4 
recruit and activate effector T cells thereby providing a mechanism to explain how 5 
HCMV infection increases hepatic immune activation in allograft rejection. 6 
 7 
Materials and Methods 8 
Human tissue and blood 9 
Liver tissue obtained from explanted livers or tissue surplus to surgical requirements 10 
was collected from patients in the Liver Unit at the Queen Elizabeth Hospital 11 
(Birmingham, UK) with informed consent.  HSEC were isolated from liver tissue and 12 
cultured as previously reported[2].  PBMC were isolated from healthy donor blood by 13 
density gradient centrifugation and T cell subsets were isolated using 14 
immunomagnetic separation or flow cytometry cell sorting. For indicated 15 
experiments, HCMV-reactive CD4 T cells were generated from CMV-seropositive 16 
donors using cell cloning by limiting dilution as described in the Supplementary 17 
Materials and Methods section. 18 
 19 
Recombinant human CMV 20 
To study endothelial HCMV infection we used the bacterial artificial chromosome 21 
(BAC)-cloned strain recombinant CMV1426 (from BAC pAL1426), which was a gift 22 
from Richard Stanton. CMV1426 contains an internal ribosomal entry site, followed 23 
by enhanced green fluorescent protein (EGFP) after UL122, a frame shift mutation in 24 
RL13[18], and the UL128 locus derived from endotheliotropic TB40-BAC4[19]. 25 
CMV1426 was propagated and purified as described in the Supplementary Materials 26 
  
 9
and Methods section. Virus was then titrated to maintain an intact EC monolayer 1 
using 0.1–0.3 multiplicity of infection (MOI) after spinfection (20 min, 800×g) and 2 
further 100 min of virus incubation in serum-free medium followed by rigorous 3 
washing to remove unbound virus. 4 
 5 
Flow-based adhesion and migration  6 
Lymphocyte interaction with confluent monolayers of HSEC was assessed in flow-7 
based adhesion assays at physiological shear stress as previously described[20]. 8 
HSEC monolayers were either CMV1426-infected or mock-infected and cultivated for 9 
subsequent 24 hours, and remained untreated or stimulated with combinations of 10 
recombinant TNF-α, IFN-γ, IFN-α, or IFN-β at 10 ng/ml for 24 hours (PeproTech, 11 
Peterborough, UK). PBL or purified T cell subsets were flowed over HSEC 12 
monolayers for 5 min followed by a washout phase of another 5 min. Cells appearing 13 
bright in phase contrast microscopy were above the endothelial monolayer, whereas 14 
those that were dark had migrated. To determine the molecular bases of the 15 
interactions, HSEC monolayers and/or lymphocytes were incubated with blocking 16 
Abs for 30 min in individual experiments as indicated and the respective isotype-17 
matched controls (IMC) (see the Supplementary Materials and Methods section). 18 
 19 
Static migration 20 
HSEC were grown until confluence in collagen-coated plates, CMV1426-infected or 21 
mock-infected, detached, and reseeded either on either collagen-coated cell culture 22 
transwell inserts with 3-µm pore size (BD Biosciences, Oxford, UK) for short-term 23 
transwell experiments or fibronectin-coated polymerized bovine collagen I plugs 24 
(Gibco, Life Technologies, Paisley, UK) for long-term experiments. In the transwell 25 
model T cells allowed to migrate across HCMV-infected or cytokine-stimulated HSEC 26 
  
 10 
to the bottom chamber within 4 hours. In the collagen model T cells were allowed to 1 
adhere to HCMV-infected or mock-infected HSEC for 2 hours, and migrate over 24-2 
48 hours into collagen. Migrated cells were retrieved using collagenase digestion and 3 
used in flow cytometry or functional assays as described in the Supplementary 4 
Materials and Methods section.  5 
 6 
Cytokine secretion  7 
Cytokines and chemokines released into the supernatant were quantified using 8 
ELISArray Kits (SABioscience/Qiagen, West Sussex, UK), ISG56-Luciferase reporter 9 
transfected Huh-7.5 cells, or the proteome profiler kit (R&D Systems, Abingdon, UK) 10 
as described in the Supplementary Materials and Methods section. 11 
 12 
T cell suppression  13 
Migrated CD4 T cells were co-cultured with CellTrace violet-labeled (Life 14 
Technologies) responder T cells from healthy donors in varying ratios in the presence 15 
of CD3/CD28 activating beads (Treg inspector; Miltenyi Biotec). Flow cytometry was 16 
carried out to determine responder cell division after 3 days (see Supplementary 17 
Materials and Methods section). 18 
 19 
Gene expression  20 
Serial analysis of gene expression (SAGE) was performed 24 hours after mock 21 
infection, cytokine stimulation with TNF-α and IFN-γ at 10 ng/ml, or infection with 22 
CMV1426 (MOI 0.3) in isolated HSEC from patients with autoimmune hepatitis, 23 
seronegative hepatitis, and alcoholic liver disease as described in the Supplementary 24 
Materials and Methods section. Modulated gene expression in CD4 memory T cells 25 
before and after endothelial transmigration (ETM) through CMV-infected HSEC was 26 
  
 11 
determined using the RT2 Profiler PCR Array Human T Helper Cell Differentiation Kit 1 
(SABiosciences/Qiagen) (see Supplementary Materials and Methods). 2 
 3 
Multicolor confocal microscopy  4 
Live-cell immunofluorescence staining of CMV1426-infected or mock-infected HSEC 5 
for ICAM-1 and LFA-3 was performed on an upright 780 ZEN laser scanning confocal 6 
microscope (Zeiss, Oberkochen, Germany) as described in the Supplementary 7 
Materials and Methods section. 8 
 9 
Statistical analysis 10 
Statistical tests were performed using Prism 5.0 software (GraphPad, La Jolla, CA). 11 
Results are expressed as mean and standard error of mean unless otherwise stated. 12 
Two-tailed Student’s t test or ANOVA with post-hoc Dunnett’s multiple comparison 13 
tests were used to determine the significance of differences between groups as 14 
appropriate. P values less than .05 were considered significant.  15 
 16 
Results 17 
HSEC are permissive for HCMV infection 18 
Infection of primary HSEC with CMV1426 (MOI 0.1-0.3) resulted in the typical 19 
cytopathic effect beginning at 24 hours post infection (p.i.) (Figure 1A). EGFP 20 
expression was seen in enlarged rounded cells and spread in culture for up to 12-14 21 
days before the monolayer was destroyed and infected cells lifted off (Figure 1B). 22 
Supernatant from infected HSEC was infective after a delay of 2 days resulting in 23 
stable HCMV concentrations in the supernatant after 6 days that were able to infect 24 
human fetal foreskin fibroblasts (HFFF2) (Figure 1C).  25 
 26 
  
 12 
Liver sinusoidal HCMV infection induces a distinct regulation of cell adhesion 1 
molecules and chemokines 2 
Serial analysis of gene expression (SAGE) in mock- and HCMV-infected HSEC 3 
revealed that among the 141 differentially regulated genes the vast majority (120) 4 
was significantly downregulated after HCMV infection. This was in sharp contrast to 5 
endothelium treated with TNF-α and IFN-γ[2], where the upregulation of gene 6 
expression dominated (Supplementary Figure S1). Analysis of the regulation of a 7 
pre-selected panel of mRNAs revealed varying upregulation of intercellular adhesion 8 
molecule-1 (ICAM-1) and the chemokines CXCL8, CXCL9, CXCL10, and CX3CL1 9 
following HCMV infection in at least two of three liver donors 24 hours p.i. (Figure 10 
2A).  11 
 12 
In addition to CXCR3 ligands, murine genes encoding CCR5 ligands (Ccl4, Ccl5) 13 
have been shown to be significantly upregulated in a model of CMV infection of liver 14 
sinusoidal EC[17]. Therefore we measured the release of the respective human 15 
chemokines in HSEC supernatants after HCMV infection. Among those, CXCL10 16 
secretion was significantly elevated following HCMV infection exceeding 1000-fold 17 
the concentrations measured for mock-infected HSEC 24 hours p.i. (Figure 2B). 18 
CXCL10 release from HSEC was dose-dependent, fell to control levels during the 19 
viral eclipse phase, and was released during viral spread with similar kinetics to 20 
CXCL8 and IL-6 (Supplementary Figure S2). Consistent with reports that ligands of 21 
CXCR3, CCR5, and CX3CR1 can be induced by type I interferons in microvascular 22 
endothelium from other organs[21], we measured a significant release of type I 23 
interferons by HSEC following HCMV infection contributing to chemokine induction 24 
(Figure 2C).  25 
 26 
  
 13 
To investigate surface cell adhesion molecule expression following replicative HCMV 1 
infection we used flow cytometry gating on EGFP-positive HCMV-infected HSEC 2 
compared to mock-infected HSEC and cytokine-stimulated HSEC known to optimally 3 
promote lymphocyte adhesion and ETM as a positive control[2]. Cultured HSEC 4 
expressed detectable levels of intercellular adhesion molecule (ICAM)-1, ICAM-2, 5 
and lymphocyte function-associated antigen 3 (LFA-3) in the absence of exogenous 6 
cytokine stimulation but no expression of vascular cell adhesion molecule-1 (VCAM-7 
1) or E-selectin and cytokine treatment strongly increased expression of VCAM-1 and 8 
ICAM-1. Following HCMV infection, there was a significant increase in ICAM-1 9 
expression, but no induction of VCAM-1, ICAM-2, E-Selectin or vascular adhesion 10 
protein-1 (VAP-1) (Figure 2D and E). Confocal microscopy of live HCMV-infected 11 
HSEC monolayers confirmed an increased ICAM-1 expression on infected HSEC 12 
with LFA-3 enrichment at intercellular junctions (Figure 2F).  13 
Viral replication was required for ICAM-1 and CXCL10 induction, which were 14 
abrogated when UV-irradiated virus was used (Figure 2B) or if cells demonstrated 15 
no viral replication (Figure 2D, Supplementary Figure 3A). Accordingly, treatment 16 
of HSEC with UV-inactivated virus did not result in a significantly increased 17 
adherence of PBMC to endothelium under flow (Supplementary Figure 3B). 18 
 19 
Liver sinusoidal HCMV infection promotes adhesion and migration of T cell subsets 20 
under flow 21 
We went on to investigate the functional consequences of HCMV infection for 22 
lymphocyte ETM under conditions of physiological shear stress[2]. When HSEC were 23 
infected with HCMV maintaining an intact monolayer at 24 hours p.i. freshly isolated 24 
allogeneic PBL bound in greater numbers to HCMV-infected endothelium compared 25 
to mock-infected endothelium and showed increased rates of ETM (Figure 3A). TNF-26 
  
 14 
α/IFN-γ-treated HSEC supported increased adhesion and migration and in some 1 
experiments this was further increased by prior HCMV infection. In contradistinction, 2 
treatment with IFN-α/IFN-β at doses of 10 ng/ml each did not alter the total number of 3 
adherent and migrating PBL (Figure 3B) consistent with a lack of upregulation of 4 
ICAM-1 following type I interferon treatment (Supplementary Figure S4). 5 
 6 
A similar response was seen when the experiments were repeated using highly pure 7 
CD4 T cells isolated from blood. Blocking antibodies against ICAM-1 significantly 8 
reduced absolute adherence and migration, whereas VAP-1 and common lymphatic 9 
endothelial and vascular endothelial receptor-1 (CLEVER-1) blocking antibodies did 10 
not show a significant effect (Figure 3C). Treatment with anti-CXCL10 antibodies did 11 
not reduce the absolute number of migrating T cells but did reduce the percentage of 12 
adherent cells undergoing ETM (Figure 3D).  13 
 14 
CMV-specific CD4 T cell clones, which secreted IFN-γ in response to autologous 15 
CMV peptide-pulsed EBV–transformed lymphoblastoid cell lines (LCL) and displayed 16 
an activated effector phenotype (CD45RO+CD62L-CD2hiCD11ahiCD18hi), bound to 17 
and migrated at 5 times greater numbers than resting CD4 T cells. HCMV infection of 18 
HSEC resulted in an increased number of cells adhering and migrating, which could 19 
be abrogated using an anti-ICAM-1 blocking antibody on endothelium (Figure 3E). In 20 
addition, expanded polyclonal CD4 CD25hi Treg also bound to HCMV-infected HSEC 21 
although at lower frequencies than the CD4 clones. Their adhesion and 22 
transmigration was reduced by approximately 50% by blocking ICAM-1 (Figure 3F) 23 
supporting the role of ICAM-1 as a predominant mechanism promoting adhesion to 24 
and migration across HCMV-infected HSEC in all investigated T cell subsets. 25 
 26 
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Effector memory T cells expressing CXCR3 and CCR5 predominantly migrate across 1 
HSEC 2 
To investigate changes in the T cell phenotype after ETM, we employed two static 3 
models. In the first model lymphocytes migrated across HSEC into collagen and 4 
remained subendothelial for 24 to 72 hours allowing us to study differentiation after 5 
migration; in the second model lymphocytes migrated across HSEC seeded onto 6 
collagen-coated 3 µm transwell filters allowing us to study early recruitment (Figure 7 
4A). In both models there were no significant differences in the distribution of 8 
migrated CD4, CD8, γδ T cells, and NKT cells between mock- and HCMV-infected 9 
HSEC in the collagen model or between cytokine-stimulated and HCMV-infected 10 
HSEC in the transwell model (Figure 4B).  11 
 12 
After migration through cytokine-treated and HCMV-infected HSEC in the transwell 13 
model, T cell populations expressing CXCR3 and/or CCR5 were increased compared 14 
to the pre-migratory cell population (Figure 3C). In addition, migrated T cells had 15 
higher surface expression of the LFA-3 ligand CD2 and the ICAM-1 ligand 16 
CD11a/CD18 (LFA-1, αLβ2 integrin) (Figure 3D). To further dissect the phenotype of 17 
CD4 T cells migrating through infected HSEC with respect to their homing and 18 
effector functions, we stained migrating CD4 T cells for the memory marker CD45RO 19 
and two lymphocyte homing receptors CD62L and CCR7. While CD4 T cells 20 
adherent to infected endothelium did not show any difference in expression of 21 
CD45RO and CD62L compared to the starting population of purified CD4 T cells, T 22 
cells that migrated across HCMV-infected endothelium where predominantly 23 
CD45RO-positive memory T cells with reduced CD62L expression (Figure 4E). 24 
CD62L-CCR7- effector memory T cells (TEM) were selectively enriched after migration 25 
through HSEC with the highest fraction being observed after migration through 26 
  
 16 
HCMV-infected HSEC (Figure 4F). To estimate whether HCMV-reactive T cells from 1 
seropositive donors were also enriched following migration of PBMC across HCMV-2 
infected HSEC we determined CD4 T cell activation in response to HCMV lysate by 3 
measuring de-novo synthesized CD154 [22]. An increased number of reactive T cells 4 
were observed migrating across infected HSEC when compared to mock-infected or 5 
cytokine stimulated endothelium but this population was not enriched for HCMV-6 
responding T cells. This suggests that the vast majority of migrating effector T cells 7 
were not HCMV-reactive (Supplementary Figure S5). 8 
 9 
Transmigration through HCMV-infected HSEC induces cell contact-dependent Th1 10 
activation of memory CD4 cells 11 
Based on our observations of increased adhesion and migration of TEM through 12 
HCMV-infected HSEC, we used purified allogeneic CD45RO+ CD4 memory T cells 13 
from CMV-positive and CMV-negative donors to study T cell activation after ETM 14 
because immunohistochemical staining of liver biopsies suggested an increased 15 
level of activated T cells within the CMV-infected liver (Supplementary Figure S6). 16 
Using the described in vitro models of T cell migration through a monolayer of 17 
endothelium, twenty-four to 48 hours after migration through HCMV-infected HSEC, 18 
CD4 memory T cells displayed increased expression of the activation markers CD69, 19 
CD71, CD25, and HLA-DR compared to pre-migratory T cells (Figure 5A and B). 20 
Upregulation of activation markers after transmigration occurred irrespective of T cell 21 
donor’s CMV serostatus and was not observed after migration across mock-infected 22 
or cytokine-stimulated endothelium (Supplementary Figure S7). CD69+ CD4 T cells 23 
that had migrated through HCMV-infected endothelium showed increased 24 
spontaneous IFN-γ secretion without further stimulation but no increase in 25 
intracellular TNF-α or IL-10 (Figure 5C), and supernatant derived from migrated CD4 26 
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memory cells contained detectable levels of IFN-γ and soluble CD154 (Figure 5D). 1 
After stimulation with PMA and ionomycin the cells secreted high levels of IL-2, TNF-2 
α and GMCSF but no detectable Th2 or Th17 cytokines (Figure 5D). After migration 3 
through HCMV-infected HSEC IFNG gene expression was strongly upregulated 4 
together with other components of Th1-differentiated CD4 T cells including the signal 5 
transducer and activator of transcription 1 (STAT1), the key regulator of Th1 6 
differentiation and driver of IFN-γ production T-bet (TBX21) and the IL-12 receptor 7 
(IL12RB2) (Figure 5E). This activation programme depended on cell-cell contact and 8 
did not occur when HSEC and memory T cells were separated by a non-cell 9 
permeable filter of 0.3 µm excluding activation by soluble factors (Figure 5F). 10 
Blocking the LFA-3/CD2 pathway by incubating HSEC with mAbs against LFA-3 11 
resulted in a 29% decrease of CD69 expressing migrated memory T cells whereas 12 
blocking mAbs against ICAM-1, CXCL10, TLR2, endothelial protein C receptor, 13 
inhibiting the JAK-STAT signaling pathway in infected HSEC (EPCR), or removing 14 
cholesterol from lipid rafts by methyl-β-cyclodextrin (MBCD) had no effect on T cell 15 
activation post migration (Figure 5F).  16 
 17 
HCMV-infected endothelium recruits functional regulatory T cells 18 
In keeping with our earlier observation that CD4 Treg showed increased migration 19 
across infected versus non-infected HSEC in flow-based adhesion assays, we found 20 
that genes associated with Treg differentiation, forkhead box P3 (FOXP3) and IL-2 21 
receptor alpha (IL2RA), were upregulated after migration through HCMV-infected 22 
endothelium  (Figure 5E). This suggests that the enrichment of CD25hi CD4 T cells 23 
after migration through HCMV-infected HSEC could be due to the recruitment and/or 24 
induction of Treg as well as activated effector cells.  25 
 26 
  
 18 
The number of early and late apoptotic cells after migration through HCMV-infected 1 
and mock-infected HSEC into collagen did not change between 24 and 72 hours 2 
excluding induction of T cell apoptosis post migration (Figure 6A). A large proportion 3 
of migrated CD25hi CD4 T cells were CD127lo with FoxP3 expression, consistent with 4 
a regulatory T cell phenotype (Figure 6B). The frequency of CD25hi expressing CD4 5 
T cells did not increase during incubation over time in the collagen model suggesting 6 
selective recruitment rather than proliferation (Figure 6C). Similar results were seen 7 
in the transwell model where HCMV-infected HSEC recruited a higher proportion of 8 
CD127loCD25hi FoxP3+ memory T cells compared with cytokine-treated HSEC at 9 
early time-points (Figure 6D). As a consequence of the increased fraction of Treg, 10 
CD4 T cells were able to suppress T cell proliferation after migration through HCMV-11 
infected endothelium when compared with T cells that migrated across cytokine-12 
stimulated HSEC (Figure 6E). 13 
 14 
Discussion 15 
HSEC represent uniquely differentiated microvascular EC that play a critical role in 16 
regulating hepatic immune responses. They are responsible for regulating the 17 
recruitment of circulating lymphocytes into the hepatic parenchyma and also 18 
contribute to hepatic immune regulation through their ability to act as APCs that 19 
under the right conditions can induce both CD8 and CD4 T cell tolerance.  These 20 
properties allow the liver to mount swift immune responses to infections such as 21 
hepatitis A whilst preventing immune activation to harmless food antigens entering 22 
via the gut.  23 
 24 
Recent evidence from murine models suggests that sinusoidal endothelium is 25 
permissive to CMV infection and can act as a source of infection for adjacent 26 
  
 19 
hepatocytes[10, 13]. MCMV infection of murine sinusoidal endothelium results in a 1 
switch from a tolerogenic to an immunogenic phenotype and promotes the ability of 2 
HSEC to induce full differentiation of cytotoxic effector CD8 T cells after cross-3 
presentation thereby breaking an important tolerogenic mechanism[17]. The clinical 4 
significance of this finding is emphasized by the increased incidence of graft rejection 5 
in liver transplant recipients with CMV infection[15, 23]. Since CMV replication is 6 
species restricted and significant diversity exists between human and murine CMV, 7 
animal models cannot be relied upon to recapitulate the events that occur in patients 8 
during clinical CMV infection. In the present study we use in vitro models of primary 9 
human cells to demonstrate how HCMV infection of HSEC promotes adhesion and 10 
migration of allogeneic T cell subsets thereby leading to an enrichment of 11 
predominantly non-virus-specific Th1-differentiated CD4 T cells and functional Treg.  12 
 13 
In contrast to hepatotropic viruses that do not replicate in HSEC[5–7], we show that 14 
inoculation of HSEC with live HCMV results in endothelial infection promoting hepatic 15 
T cell recruitment via upregulation of ICAM-1 surface expression and the release of 16 
chemokine ligands for the inflammatory chemokine receptors CXCR3 and CCR5 17 
(Figure 7). Our findings are in line with histopathological studies describing 18 
increased ICAM-1 expression on liver endothelium in biopsies from CMV-infected 19 
liver transplants[24] and provide a mechanism by which sinusoidal EC regulate 20 
CXCR3-dependent accumulation of T cells in the murine model[25]. Importantly, the 21 
inflammatory endothelial phenotype induced by CMV infection promoting ETM 22 
differed from that seen in response to inflammatory cytokines suggesting that CMV 23 
infection has a specific effect on endothelial activation.  24 
 25 
  
 20 
HCMV-infected HSEC preferentially recruited particular subsets of T cells. Memory 1 
CD4 T cells that were CD45RO+CCR7−CD62L−, CXCR3, and/or CCR5 positive with 2 
high surface expression of CD2 and αLβ2 integrins were selectively enriched following 3 
ETM corresponding to the phenotype of T cells infiltrating inflamed tissues in 4 
vivo[26]. Furthermore these memory T cells were enriched for IFN-γ secreting Th1 5 
cells and expressed markers of recent activation. This activation was not antigen-6 
specific but in part dependent on adhesion through the LFA-3-CD2 pathway in an 7 
allogeneic context. Thus virally infected HCMV endothelium is able to promote the 8 
recruitment and differentiation of particular T cell subsets even if these cells are not 9 
antigen-specific.  10 
 11 
In contrast to naïve CD4 T cells and central memory T cells, which must be activated 12 
in lymphoid organs before they develop an effector phenotype, HCMV-infected cells 13 
could activate polyclonal T cells to secrete Th1 cytokines immediately on recruitment 14 
into the liver. This is consistent with previous studies showing that IFN-γ secretion by 15 
CD4 TEM in response to allogeneic EC is dependent on LFA-3 engagement but 16 
independent of CD80 and CD86 stimulation in co-culture models[27]. In our study 17 
adhesion to HCMV-infected HSEC alone was insufficient to induce significant T cell 18 
activation which required ETM. This mechanism could rapidly deliver IFN-γ secreting 19 
effector cells into the CMV-infected liver parenchyma. The clinical relevance of our 20 
study is supported by a large observational study showing the presence of similarly 21 
activated T cells in the hepatic parenchyma of CMV-infected allografts[24]. CD4 TEM 22 
are important mediators of allograft rejection[27] suggesting that the recruitment and 23 
activation of alloreactive TEM through HCMV-infected HSEC could explain how CMV 24 
infection can trigger allograft rejection. 25 
 26 
  
 21 
Interestingly, we also observed an ICAM-1-dependent recruitment of functional Treg 1 
by HCMV-infected HSEC as a presumably important mechanism to counterbalance 2 
the pro-inflammatory CD4 T cell recruitment in an attempt to limit bystander tissue 3 
injury. The functional consequences of the increased T cell recruitment through 4 
CMV-infected HSEC may depend on the balance and kinetics of effector T cell 5 
versus Treg recruitment mediating liver allograft tolerance[28] but also promoting 6 
persistent viral infection[29]. Indeed, we have previously demonstrated that both Treg 7 
and effector T cells employ identical mechanisms, namely CXCR3/CXCR3-ligand 8 
and αLβ2/ICAM-1 interaction, in order to migrate across cytokine-stimulated hepatic 9 
endothelium[20,30].  10 
 11 
In summary, we show for the first time how HCMV infection of sinusoidal endothelium 12 
modulates the recruitment and differentiation of T cell subsets using human primary 13 
cells. Despite the limitations of such in vitro models, our work has implications for 14 
how viral infection can modulate hepatic immunity, particularly in the context of liver 15 
transplantation. Further work is required to clarify how the critical balance of 16 
protective anti-viral effector T cells, potentially harmful non-specific effector T cells 17 
and tolerogenic regulatory T cells is controlled during hepatic HCMV-infection in the 18 
context of immunosuppression. 19 
  20 
  
 22 
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Figure legends 1 
Figure 1: HSEC are permissive for HCMV infection.  2 
(A) Morphology of mock-infected (top) and CMV1426-infected (bottom) HSEC 3 
monolayers 24 hours p.i. illustrating the cytopathic effect of HCMV. (B) EGFP 4 
expression demonstrating viral spread of HCMV 2-12 days p.i. in infected HSEC 5 
monolayers. (C) Representative one-step growth curve of supernatant HCMV 6 
infectivity in as determined by plaque assay on HFFF2 (circles) and increasing 7 
percentage of EGFP-positive HSEC (diamonds) as determined by flow cytometry. 8 
 9 
Figure 2. HCMV infection regulates HSEC adhesion molecule expression and 10 
chemokine release  11 
(A) Heat map showing normalized expression of human target genes of interest 12 
following infection of HSEC with CMV1426. (B) Chemokine concentrations in serum-13 
containing conditioned supernatant HCMV-infection, mock-infection or inoculation 14 
with UV-irradiated HCMV (4-6 independent experiments, Dunnett’s post hoc test). (C) 15 
Supernatant from HCMV-infected HSEC stimulates the type I IFN target gene ISG56 16 
in Huh-7.5 hepatoma cells in a luciferase reporter assay (4 independent experiments, 17 
t test). (D) Representative flow cytometry plots of side scatter (SSC) and EGFP 18 
expression in HCMV-infected or mock-infected HSEC 7d p.i. showing increasing 19 
ICAM-1 surface expression in HSEC without (dotted), with moderate (grey), and with 20 
high (solid black) EGFP expression. (E) Surface molecule expression on mock-21 
infected (white), EGFP-positive HCMV-infected (grey) and cytokine-treated (black) 22 
HSEC 24 hours p.i. as determined by flow cytometry (3-8 independent experiments, t 23 
test). (F) Representative confocal microscopy of HSEC monolayers after live surface 24 
staining for ICAM-1 (red) and LFA-3 (blue) in HCMV-infected and mock-infected 25 
HSEC.  26 
  
 27 
 1 
Figure 3: HCMV-infected HSEC recruit T cells via ICAM-1 and CXCL-10 under flow 2 
(A) Representative phase contrast microscopy video stills showing adherent non-3 
migrating (white arrows) and migrating (black arrows) PBL to mock-infected, 4 
cytokine-treated and HCMV-infected HSEC. HCMV-infected HSEC with cytopathic 5 
effect are shown (arrow heads). (B) Quantification of adherent non-migrating and 6 
migrating allogeneic PBL in flow-based adhesion assays to mock-infected, type-I 7 
interferon-treated and HCMV-infected HSEC. TNF-α and IFN-γ-stimulated HSEC are 8 
shown as a positive control (at least 4 independent experiments, Dunnett’s post hoc 9 
test of total cells adherent cells). (C) Adherent non-migrating and migrating 10 
allogeneic CD4 T cells after flow over mock-infected and HCMV-infected HSEC 11 
showing significant decrease in total adherent cells after treatment of HSEC with anti-12 
ICAM-1 mAbs (6 independent experiments, t test). (D) Reduction of the frequency of 13 
transmigrating among total adherent CD4 T cells to HCMV-infected HSEC after 14 
treatment with anti-CXCL10 antibodies (before-after plot, means, and SEM are 15 
shown, paired t-test). (E) Representative phase contrast microscopy of CMV-specific 16 
effector T cell clones adherent to HCMV-infected HSEC treated with mAbs against 17 
ICAM-1 (top). Quantification of adherent and migrating CMV-specific effector CD4 T 18 
cell clones on mock-infected and HCMV-infected HSEC (7 independent experiments, 19 
t test) and its inhibition by monoclonal antibodies against ICAM-1 (2-15 independent 20 
experiments, t test of total adherent cells) are shown. (F) Quantification of adherent 21 
and migrating polyclonal regulatory CD4 T cells on HCMV-infected HSEC and after 22 
treatment of HSEC with anti-ICAM-1 or T cells with anti-CXCR3 (6 independent 23 
experiments, t test). 24 
 25 
Figure 4: CMV-infected HSEC recruit activated effector memory CD4 T cells  26 
  
 28 
(A) Schematic illustration of the two static ETM models employed as described in the 1 
Materials and Methods section. (B) Frequency of T cell subsets among CD3 T cells 2 
that have migrated into collagen (left panel) or across the transwell (right panel) using 3 
mock-infected, cytokine-treated, or HCMV-infected HSEC compared to the starting 4 
population. In transwell models CD56 staining was not performed, thus NKT cells are 5 
not indicated (4-8 independent experiments). (C) Percentage of chemokine receptor 6 
expressing T cells and (D) median FI of CD2, CD11a, and CD18 in the starting 7 
population and after migration through cytokine-stimulated or HCMV-infected HSEC 8 
in the transwell model (boxplots from 4 and mean+SEM from 3 independent 9 
experiments). (E) Representative expression of CD62L and CD45RO on CD4 T cells 10 
before ETM (left), after adherence to HCMV-infected HSEC (top right) and after 11 
migration across HCMV-infected HSEC into collagen (bottom right). (F) Fractions of 12 
central (CCR7+CD62L+; light grey) and effector (CCR7-/CD62L-; dark grey) CD4 13 
memory T cells before and after migration through mock-infected, cytokine-treated, 14 
or HCMV-infected HSEC into collagen (8-9 independent experiments, Dunnett’s post 15 
hoc test comparing fractions of TEM). 16 
 17 
Figure 5: Allogeneic T cells demonstrate Th1 activation after migration across 18 
HCMV-infected HSEC 19 
(A) Representative plots of activation marker expression on isolated CD4 memory T 20 
cells left untreated without endothelial contact (ctrl) and 24 hours after migration 21 
through HCMV-infected or mock-infected HSEC into collagen. (B) Fractions of 22 
surface marker-positive CD4 memory T cells within CD4 T cells before and after 23 
migration through HCMV-infected or mock-infected HSEC (5-16 independent 24 
experiments, Dunnett’s post hoc test). (C) Representative plots of CD69 expression 25 
versus intracellular cytokine staining of CD4 memory T cells after migration through 26 
  
 29 
mock-infected, cytokine-stimulated and HCMV-infected HSEC into collagen. (D) 1 
Representative images of nitrocellulose membranes with spotted antibodies against 2 
several cytokines (bottom) and densitometric quantification as normalized mean pixel 3 
density of chemiluminescence of those cytokines (top) in supernatants from CD4 4 
memory T cells after migration through HCMV-infected HSEC into collagen.  5 
Retrieved T cells either remained unstimulated or were treated with PMA/ionomycin 6 
before analysis. (E) Waterfall plot of more than two-fold regulated genes in CD4 7 
memory T cells following ETM across HCMV-infected HSEC compared to the starting 8 
population as determined by real-time RT PCR array. (F) Left: Expression of CD69 9 
on CD4 memory T cells remains unchanged when memory T cells are separated 10 
from HCMV-infected HSEC by transwell membranes with 0.3 µm pores. Right: 11 
Significant change in relative surface expression of CD69 on CD4 memory T cells 12 
after incubation of HCMV-infected HSEC with functional Abs against LFA-3 but not 13 
with blocking Abs against MHC class II, ICAM-1, CXCL10, TLR2 or EPCR or with 14 
JAK inhibitor I or methyl beta cyclodextrin (MBCD) in comparison to untreated 15 
HCMV-infected HSEC (3-11 independent experiments, one-sample t-test) 16 
 17 
Figure 6: CMV-infected human sinusoidal endothelial cells recruit functional 18 
regulatory T cells 19 
(A) Representative plot showing propidium iodide (PI) and annexin V staining CD4 20 
memory T cells 72 hours after migration through mock-infected or HCMV-infected 21 
HSEC into collagen showing unchanged levels of early and late apoptosis. (B) 22 
Representative density plot of CD127 and CD25 and histogram plot of intracellular 23 
FoxP3 expression in memory CD4 T cells that migrated across HCMV-infected 24 
HSEC showing highest expression of FoxP3 in the CD25hiCD127lo population (IMC: 25 
grey). (C) Time-dependent increase of the percentage of CD25hi and CD25lo-26 
  
 30 
expressing CD4 memory T cells after migration across mock-infected or HCMV-1 
infected HSEC into collagen compared to the pre-migratory population. (D) 2 
Frequency of CD25hiCD127lo cells among CD4 T cells before and after migration 3 
through cytokine-stimulated or HCMV-infected HSEC in the transwell model (4 4 
independent experiments; Dunnett’s post hoc test; mean percentage of FoxP3+ as 5 
black inserts). (E) Effector CD4 T cell proliferation as representative plots and 6 
quantified after stimulation with CD2/CD3/CD28 beads and co-incubated with CD4 7 
memory T cells that migrated across cytokine-stimulated, mock-infected, or HCMV-8 
infected HSEC in different ratios of effector cells to migrated cells (1:1 to 1:4) (3 9 
independent experiments, t-test). T cells that have not migrated across HSEC are 10 
shown as a control (start). 11 
  12 
Figure 7. Schematic representation of T cell recruitment across HCMV-infected 13 
sinusoidal endothelium 14 
(A) HCMV infection of HSEC results in upregulated ICAM-1 expression and release 15 
of type-I interferons and interferon-regulated chemokines. (B) Allogeneic effector 16 
memory CD4 T cells and suppressive regulatory T cells predominantly migrate 17 
across HCMV-infected endothelium in an LFA-1/ICAM-1 and CXCR3/CXCL10-18 
dependent manner. Recruited effector T cells show an activated Th1 Phenotype, 19 
which is in part mediated by the interaction of CD2 with LFA-3. Proposed 20 
consequences of the differential T cell recruitment into the liver and the additional 21 
impact of immunosuppression are indicated in italic font. 22 
 23 
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